Smitht Dupilumab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

United statesSan antonioSmitht dupilumabMarcus maurerDrug administrationAmerican academy of allergyComplete response letterBiologics license applicationItch severity scoreUrticaria activity scoreCharite universitatsmedizin berlinAmerican academyDermatology life quality indexPublished octoberSignificantly reduces itchPatients with chronic spontaneous urticaria